Therapy After CDK Inhibition in Metastatic HR+ Breast...

Therapy After CDK Inhibition in Metastatic HR+ Breast Cancer
Published in Metastatic Breast Cancer and Journal Scan / Review · June 04, 2020

TAKE-HOME MESSAGEAs the use of CDK4/6 inhibitor regimens has moved into standard first-line therapies, treatment strategies for resistance/relapse have also become increasingly important. Data are lacking to guide the use of endocrine monotherapy, combination endocrine therapy with PI3K/mTOR inhibitors, and chemotherapy following resistance in this setting. In this review, the authors review the mechanisms of resistance, existing data, and new approaches in this patient population.Further research is needed to facilitate the identification of patients likely to benefit from early, escalated regimens and those with treatment-sensitive disease who may benefit from a sequential approach to treatment.– Paul J. Hampel, MD

https://www.practiceupdate.com/c/101172/67/13/?elsca1=emc_enews_weekinreview&elsca2=email&elsca3=practiceupdate_metastaticbreastcancer&elsca4=metastaticbreastcancer&elsca5=newsletter&rid=NDQ3MTgxOTYwMzc4S0&lid=10332481

Is this combination treatment a blue sky opportunity for Paxalisib ?

Regards.